Update on Analyst Recommendations for Alexion
According to a Bloomberg consensus of 21 brokerage firms on July 28, 2016, after Alexion’s 2Q16 earnings release, 76.2% of analysts recommended “buys.”
In 2Q16, Strensiq added $45 million to Alexion Pharmaceuticals’ (ALXN) top line. The drug is indicated for HPP (hypophosphatasia).
Alexion (ALXN) has been serving the atypical hemolytic uremic syndrome, or aHUS, market for the past five years.
Soliris is Alexion’s (ALXN) highly innovative drug. The drug’s revenue grew to $701 million, translating to a 10% YoY (year-over-year) growth in 2Q16.
During the second quarter of 2016, Alexion (ALXN) witnessed 23% volume growth, resulting in an 18% annual revenue growth.
In 2Q16, Alexion Pharmaceuticals (ALXN) earned $753 million, reflecting an 18% YoY (year-over-year) growth.
Alexion Pharmaceuticals released its earnings for 2Q16 on July 28, reporting revenues of $753.1 million, which surpassed Wall Street analyst estimates.
In 2Q16, Amgen’s (AMGN) anti-inflammation drug Enbrel saw sales of about $1.5 billion, a 10% rise from the $1.3 billion it earned in 2Q15.
A Bloomberg survey reported that 50.0% of analysts gave Amgen “buy” recommendations, while 50.0% gave the company “hold” recommendations.
While focusing on its growth products, Amgen has also been actively involved in managing the life cycles of its mature brands Neupogen and Neulasta.
Amgen (AMGN) believes that Repatha will be widely accepted as a major cardiovascular therapy for high-risk patients.
Despite tough competition from peers such as Celgene and Johnson & Johnson in 2Q16, Amgen’s Kyprolis witnessed a 24% year-over-year rise in total units sold.
In 2Q16, Amgen’s (AMGN) bone health drug Xgeva managed to earn revenue worth $381 million in 2Q16, a year-over-year (or YoY) revenue rise of about 15%.
Amgen’s (AMGN) bone health drugs Prolia and Xgeva earn a combined $3 billion in revenue annually.
Amgen declared its 2Q16 earnings on July 27, 2016. The company reported diluted earnings per share of about $2.52 in 2Q16, a year-over-year rise of ~11.4%.
According to a Bloomberg consensus of 23 brokerage firms surveyed on July 28, 2016, 69.6% of the brokerage firms rated Vertex as a “buy,” while 30.4% of the broker firms rated the company as a “hold.”
On July 6, 2016, Vertex Pharmaceuticals (VRTX) entered into a collaboration agreement with Moderna Therapeutics. Moderna’s expertise in mRNA would enable Vertex to discover and develop novel drugs with the ability to increase CFTR protein expression.
In fiscal 2016, Kalydeco is expected to generate $685 million–$705 million. There are ~4,000 eligible patients for the drug.
In 2Q16, Orkambi’s contribution to Vertex Pharmaceuticals’s (VRTX) total sales stood at $245 million, 57.5% of its cystic fibrosis product portfolio.
During the second quarter of 2016, Vertex Pharmaceuticals (VRTX) earned $431.6 million. Total cystic fibrosis (or CF) drugs sales stood at $426 million.